Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1993-11-17
1995-07-25
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
5142375, 5142395, 514252, 514255, 514316, 514319, 514325, 514649, 544 79, 544156, 544357, 544380, 546191, 546204, 552247, 552255, A61K 31135, A61K 3155, A61K 31535, A61K 31445
Patent
active
054362431
ABSTRACT:
Potentiating agents inhibit the development of multidrug resistance, reduce drug-resistance in drug-resistant tumors, or sensitize tumors to antineoplastic drugs, thereby potentiating the effect of antineoplastic agents. The potentiating agents are aminoanthraquinones, preferably 1,4-bis(N-substituted) amino anthraquinones, and pharmaceutically acceptable salts thereof.
REFERENCES:
patent: 3960751 (1976-06-01), Moriyama et al.
patent: 4197249 (1980-04-01), Murdock et al.
patent: 4310666 (1982-01-01), Zee-Cheng et l.
patent: 4526989 (1985-07-01), Murdock et al.
patent: 4540788 (1985-09-01), Murdock
patent: 4598155 (1986-07-01), Adam
patent: 4675283 (1987-06-01), Roninson
patent: 4732893 (1988-03-01), Pasini et al.
patent: 4762648 (1988-09-01), Stache et al.
patent: 4765972 (1988-08-01), Safa et al.
patent: 4782056 (1988-11-01), Rosner et al.
patent: 4816450 (1989-03-01), Bell et al.
patent: 4837306 (1989-06-01), Ling et al.
patent: 4894451 (1990-01-01), Krapcho et al.
patent: 4897403 (1990-01-01), Martin et al.
patent: 4904582 (1990-02-01), Tullis
patent: 4911924 (1990-03-01), Griffith et al.
patent: 4923871 (1990-05-01), Inaba et al.
patent: 4973675 (1990-11-01), Israel et al.
patent: 4990538 (1991-02-01), Harris et al.
patent: 4996321 (1991-02-01), Baldwin et al.
patent: 4999344 (1991-03-01), Jett-Tilton et al.
patent: 5004758 (1991-04-01), Boehm et al.
patent: 5005588 (1991-04-01), Rubin
patent: 5021426 (1991-06-01), Baldwin et al.
patent: 5025020 (1991-06-01), Van Dyke
patent: 5055459 (1991-10-01), Andersson et al.
patent: 5091552 (1992-02-01), Farquhar
patent: 5104858 (1992-04-01), Hait et al.
patent: 5112817 (1992-05-01), Fukazawa et al.
patent: 5114919 (1992-05-01), Baldwin et al.
patent: 5114951 (1992-05-01), King
patent: 5124330 (1992-06-01), King
patent: 5124338 (1992-06-01), King
patent: 5124339 (1992-06-01), King
patent: 5130303 (1992-07-01), Akiyama et al.
patent: 5134168 (1992-07-01), Bitonti et al.
patent: 5160727 (1992-11-01), Klohs et al.
patent: 5173486 (1992-12-01), Monkovic et al.
patent: 5182267 (1993-01-01), Ogawa et al.
patent: 5182293 (1993-01-01), Sunkara et al.
patent: 5182387 (1993-01-01), Freedman et al.
patent: 5187266 (1993-02-01), Farquhar et al.
patent: 5190957 (1993-03-01), Sunkara et al.
Ogasawara et al., "Potentiation of Vincristine Cytotoxicity by Ruginone B1 and Piperasfizine A in Human Moser and K562 Cells-Mode of Action", J. Antibiotics, 45(1):129-132(1992).
Murdock et al., "Antitumor Agents. 1.1,4-Bis[(aminoalky)amino]-9,10-anthracenediones", J. Medicinal Chemistry, 22(9):10214-1030(1979).
ZEE-Cheng et al., "Antineoplastic Agents. Structure-Activity Relationship Study of Bis(substituted aminoalkylamino) Anthraquinones", J. Medicinal Chemsitry, 21(3):291-294(1978).
International Search Report dated Mar. 17, 1995 for International Application No. PCT/US94/13235.
Sachs, et al., "Protein Kinase C (PKC) Inhibitors Increase Drug Accumulation and are Cytotoxic to a Human Multidrug Resistant (MDR) Breast Cancer Line", Proc. Amer. Assoc. for Cancer Res., 31:359, Abstract 2128, 1990.
Ballas, et al., "Mitoxantrone Inhibits Serine/Threonine Kineases Associated with Signal Transduction and Milogenesis", Proc. Amer. Assoc. Cancer Res., 32:394, Abstract 2344, 1991.
Sachs, et al., "Protein Kinase C Inhibitors Increase Drug Accumulation and Decrease Resistance of Multidrug Resistant Cell Lines", Proc. Amer. Assoc. Cancer Res., 32:373, Abstract 2218, 1991.
Fine, "Multidrug Resistance", Pinedo, et al., (eds) Cancer Chemotherapy and Biological Response Modifiers, pp. 73-84, NY; Elsevier Scientific Publishers, 1988.
Ford, et al., "Pharmacology of Drugs that Alter Multidrug Resistance in Cancer", Pharmacological Reviews 42(3);155-199(1990).
Bellamy, et al., "The Clinical Relevance of Multidrug Resistance", Cancer Investigation, 8(5):547-562(1990).
Ford, et al., "Cellular and Bilchemical Characterization of Thioxanthenes for Reversal of Multidrug Resistance in Human and Murine Cell Lines", Cancer Res., 50:1748-1756(1990).
Ford, et al., "Structural Features Determining Activity of Phenothiazines and Related Drugs for Inhibition of Cell Growth and Reversal of Multidrug Resistance", Molecular Pharmacology, 35:105-115(1988).
Pearce, et al., "Essential Features of the P-glycoprotein Pharmacophore as Defined by a Series of Reserpine Analogs that Modulate Multidrug Resistance", Proc. Natl. Acad. Sci. USA, 86:5128-5132(1989).
Zamora, et al., "Physical-Chemical Properties Shared by Compounds that Modulate Multidrug Resistance in Human Leukemic Cells", Molecular Pharmacology, 33:454-462(1988).
Cornwall, et al., "Increased Vinblastine Binding to Membrane Vesicles from Multidrug-Resistant KB Cells", J. Biol. Chem. 261(17):7921-7928(1986).
Cornwell, et al., "Certain Calcium Channel Blockers Bind Specifically to Multidrug-Resistant Human KB Carcinoma Membrane Vesicles and Inhibit Drug Binding to P-glycoprotein", J. Biol. Chem., 262(5):2166-2170(1987).
Cornwell, et al., "Membrane Vesicles from Multidrug-Resistant Human Cancer Cells Contain a Specific 150-to 170-kDa Protein Detected by Photoaffinity Labeling", Proc. Natl. Acad. Sci. USA, 83:3847-3850(1986).
Naito, et al., "ATP/Mg.sup.2+ -Dependent Binding of Vincristine to the Plasma Membrane of Multidrug-Resistant K562 Cells", J. Biol. Chem., 263(24):11887-11891(1988).
Safa, et al., "Identification of the Multidrug Resistance-Related Membrane Glycoprotein as an Acceptor for Calcium Channel Blockers", J. Biol. Chem., 262(16):7864-7888(1987).
Tamai, et al., "Competitive Interaction of Cyclosporins with the Vinca Alkaloid-Binding Site of P-glycoprotein in Multidrug-Resistant Cells", J. Biol. Chem., 265(27):16509-16513(1990).
Center, et al., "Mechanisims Regulating Cell Resistance to Adrimycin", Ciochem. Pharma. 34(9):1471-1476(1985).
Hamada, et al., "Phosphorylation of the M,170,000 to 180,000 Glycoprotein Specific to Multidrug-Resistant Tumor Cells: Effects of Verapamil, Thrfluoperazine, and Phorbot Esters", Cancer Research 47:2869-2865(1987).
Meyers, "Protein Phosphorylation of Multidrug-Resistant Chinese Hamster Cells", Cancer Communications, 4(4):23.gtoreq.241(1989).
Blobe, et al., "Selective Regulation of Expression of Protein Kinase C (PKC) Isoenzymes in Multidrug-Resistant MCF-7 Cells", J. Biol. Chem., 268(1):658-664(1993).
Chambers, et al., "Protein Kinase C Phosphorylates P-glycoprotein in Multidrug Resistant Human KB Carcinoma Cells", J. Biol. Chem., 265(13):7679-7686(1990).
Fine, et al., "Phorbol Esters Induce Multidrug Resistance in Human Breast Cancer Cells", Proc. Natl. Acad. Sci. USA, 85:582-586(1988).
Fojo, et al., "Expression of a Multidrug-Resistance Gene in Human Tumors and Tissues", Proc. Natl. Acad. Sci. USA, 84:265-269(1987).
Dalton, et al., "Drug-Resistance in Multiple Myeloma and Non-Hodgkins'a Lymphoma: Detection of P-Glycoprotein and Potential Circumvention by Addition of Verspamil toChemotherapy", J. Clin. Oncology, 7(4):415-424(1989).
Ozols, et al., "Verapamil and Adriamycin in the treatment of Drug-Resistant Ovarian Cancer Patients", J. Clin. Oncology, 5(4)641-647(1987).
Ballas Lawrence M
Bell Robert
Carroll R. Ivy
Fine Robert L.
Sachs Clifford W.
Pharmaceuticals Corporation
Raymond Richard L.
Research Triangle Institute Duke University
LandOfFree
Aminoanthraquinone derivatives to combat multidrug resistance does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aminoanthraquinone derivatives to combat multidrug resistance, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aminoanthraquinone derivatives to combat multidrug resistance will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-739755